Compare American Airlines Group Inc (AAL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs Novartis AG — how do they compare? American Airlines Group Inc trades at $15.32 (market cap $10.55B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 28.3× American Airlines Group Inc's market cap, and Novartis AG pays a 3.02% dividend while American Airlines Group Inc pays none. Which is the better fit depends on your goals.
| AAL | NVS | |
|---|---|---|
Market Cap | $10.55B | $298.18B |
Sector | Industrials | Health |
52-Week High | $18.15 | $168.62 |
52-Week Low | $10.18 | $119.31 |
Enterprise Value | $38.51B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAL trades at $15.94, down 0.56% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue growth is steady, reaching $54.63 billion in 2025, though net income margins are thin at 0.2%. Debt-to-asset ratios have improved to 47.25% in 2025, but negative shareholder equity remains a concern. Recent news highlights advancements in sustainable aviation fuel and premium revenue growth.
The outlook is cautiously optimistic, supported by analyst consensus favoring buy ratings (44.74%) and a $19.63 price target, implying 23% upside. Key opportunities include robust premium demand and cost management, while risks involve fuel cost volatility, high debt, and competitive pressures. Earnings execution and fuel price trends will be critical for sustained stock performance.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
